abstract |
The present invention provides a pharmaceutical composition comprising an effective amount of a covalent TEC family kinase inhibitor for increasing the Th1: Th2 biomarker ratio in a subject with cancer. The Th1 biomarker is selected from IFN-γ, IL-2, IL-12, or a combination thereof, and the Th2 biomarker is IL-10, IL-4, IL-13, or these A pharmaceutical composition wherein the covalent TEC family kinase inhibitor is ibrutinib. [Selection figure] None |